195 related articles for article (PubMed ID: 25885222)
1. Understanding the molecular basis of EGFR kinase domain/MIG-6 peptide recognition complex using computational analyses.
Moonrin N; Songtawee N; Rattanabunyong S; Chunsrivirot S; Mokmak W; Tongsima S; Choowongkomon K
BMC Bioinformatics; 2015 Mar; 16():103. PubMed ID: 25885222
[TBL] [Abstract][Full Text] [Related]
2. Molecular determinants of epidermal growth factor binding: a molecular dynamics study.
Sanders JM; Wampole ME; Thakur ML; Wickstrom E
PLoS One; 2013; 8(1):e54136. PubMed ID: 23382875
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
Zhang X; Pickin KA; Bose R; Jura N; Cole PA; Kuriyan J
Nature; 2007 Nov; 450(7170):741-4. PubMed ID: 18046415
[TBL] [Abstract][Full Text] [Related]
4. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
[TBL] [Abstract][Full Text] [Related]
5. Exploring the interactions of EGFR with phosphorylated Mig6 by molecular dynamics simulations and MM-PBSA calculations.
Zhang Y; Zheng QC
J Theor Biol; 2018 Jun; 447():118-125. PubMed ID: 29574142
[TBL] [Abstract][Full Text] [Related]
6. Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR.
Yu XD; Yang R; Leng CJ
Comput Biol Chem; 2016 Apr; 61():251-7. PubMed ID: 26967626
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
8. Rational Optimization of Tumor Suppressor-Derived Peptide Inhibitor Selectivity between Oncogene Tyrosine Kinases ErbB1 and ErbB2.
Deng Y; Li J
Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131383
[TBL] [Abstract][Full Text] [Related]
9. Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Li ZX; Qu LY; Wen H; Zhong HS; Xu K; Qiu XS; Wang EH
Int J Clin Exp Pathol; 2014; 7(10):7304-11. PubMed ID: 25400829
[TBL] [Abstract][Full Text] [Related]
10. Chk1 phosphorylates the tumour suppressor Mig-6, regulating the activation of EGF signalling.
Liu N; Matsumoto M; Kitagawa K; Kotake Y; Suzuki S; Shirasawa S; Nakayama KI; Nakanishi M; Niida H; Kitagawa M
EMBO J; 2012 May; 31(10):2365-77. PubMed ID: 22505024
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Cdc42 is essential for Mig-6 suppression of cell migration induced by EGF.
Jiang X; Niu M; Chen D; Chen J; Cao Y; Li X; Ying H; Bergholz J; Zhang Y; Xiao ZX
Oncotarget; 2016 Aug; 7(31):49180-49193. PubMed ID: 27341132
[TBL] [Abstract][Full Text] [Related]
12. Coupled folding-upon-binding of human tumor suppressor MIG6 to lung cancer EGFR kinase domain and molecular trimming/stapling of MIG6-derived β-hairpins to target the coupling event.
He Q; Xu S; Ma X; Ling T; Feng W; Lu X; Liu W; Chen Z
Eur Biophys J; 2023 Feb; 52(1-2):17-25. PubMed ID: 36547692
[TBL] [Abstract][Full Text] [Related]
13. Src defines a new pool of EGFR substrates.
Michael N; Jura N
Nat Struct Mol Biol; 2015 Dec; 22(12):945-7. PubMed ID: 26643845
[No Abstract] [Full Text] [Related]
14. Mig-6 controls EGFR trafficking and suppresses gliomagenesis.
Ying H; Zheng H; Scott K; Wiedemeyer R; Yan H; Lim C; Huang J; Dhakal S; Ivanova E; Xiao Y; Zhang H; Hu J; Stommel JM; Lee MA; Chen AJ; Paik JH; Segatto O; Brennan C; Elferink LA; Wang YA; Chin L; DePinho RA
Proc Natl Acad Sci U S A; 2010 Apr; 107(15):6912-7. PubMed ID: 20351267
[TBL] [Abstract][Full Text] [Related]
15. Structure-based inhibitory peptide design targeting peptide-substrate binding site in EGFR tyrosine kinase.
Tavakoli F; Ganjalikhany MR
PLoS One; 2019; 14(5):e0217031. PubMed ID: 31116768
[TBL] [Abstract][Full Text] [Related]
16. Understanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1.
Yan C; Kaoud T; Lee S; Dalby KN; Ren P
J Phys Chem B; 2011 Feb; 115(6):1491-502. PubMed ID: 21261310
[TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics simulation of the interactions between EHD1 EH domain and multiple peptides.
Yu H; Wang MJ; Xuan NX; Shang ZC; Wu J
J Zhejiang Univ Sci B; 2015 Oct; 16(10):883-96. PubMed ID: 26465136
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of Mig-6 in nonsmall-cell lung cancer is associated with EGFR signaling.
Li Z; Dong Q; Wang Y; Qu L; Qiu X; Wang E
Mol Carcinog; 2012 Jul; 51(7):522-34. PubMed ID: 21739478
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases.
Shih AJ; Telesco SE; Choi SH; Lemmon MA; Radhakrishnan R
Biochem J; 2011 Jun; 436(2):241-51. PubMed ID: 21426301
[TBL] [Abstract][Full Text] [Related]
20. Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6.
Park E; Kim N; Ficarro SB; Zhang Y; Lee BI; Cho A; Kim K; Park AKJ; Park WY; Murray B; Meyerson M; Beroukhim R; Marto JA; Cho J; Eck MJ
Nat Struct Mol Biol; 2015 Sep; 22(9):703-711. PubMed ID: 26280531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
